At the European Society for the Study of Diabetes (EASD) Annual Meeting in Barcelona, European Endocrinology editorial board member and EASD Senior Vice President and Chair Postgraduate Education Chantal Mathieu discusses the results of the highly anticipated VERIFY study and the latest advances in adjunct therapies in type 1 diabetes.
1. Can you summarise the results of the VERIFY study? (0:05)
2. How will this impact the future of Type 2 diabetes treatment? (1:56)
3. Is there added value to adding SGLT2 inhibitors to insulin therapy for people with type 1 diabetes? (2:50)
4. How can diabetic ketoacidosis be avoided in patients with type 1 diabetes being treated with an SGLT2 inhibitor? (4:10)
5. What are the major risks to the patients and how may these be overcome? (6:06)
Chantal Mathieu serves or has served on the advisory panel for Novo Nordisk, Sanofi, Merck Sharp and Dohme Ltd., Eli Lilly and Company, Novartis, AstraZeneca, Boehringer Ingelheim, Hanmi Pharmaceuticals, Roche, Medtronic, ActoBio Therapeutics, Pfizer, Dianax and UCB. Financial compensation for these activities has been received by KU Leuven; KU Leuven has received research support for CM from Medtronic, Novo Nordisk, Sanofi, Merck Sharp and Dohme Ltd., Eli Lilly and Company, Roche, Abbott, ActoBio Therapeutics and Novartis; CM serves or has served on the speakers bureau for Novo Nordisk, Sanofi, Merck Sharp and Dohme, Eli Lilly and Company, Boehringer Ingelheim, Astra Zeneca and Novartis. Financial compensation for these activities has been received by KU Leuven.
Filmed at the Annual Meeting of the European Association of the Study of Diabetes (EASD) Barcelona, Spain 2019.
Share this Video
Related Videos In Diabetes
Matthew Budoff, ENDO 2021: Findings from a Substudy of the VERTIS CV Trial – Ertugliflozin for T2DM & ASCVD
We caught up with Professor Matthew Budoff (UCLA and Lundquist Institute, Torrance, CA, US) to discuss ertugliflozin in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease inadequately controlled with metformin and sulfonylurea (Clinical Trial Identifier: NCT01986881). ‘Efficacy and Safety of Ertugliflozin in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease […]
Insulin at 100: a life-saving discovery but more remains to be done
2021 marks the centenary of the discovery of insulin. It is important to remind ourselves that this life-saving medication still remains beyond the reach of many people with diabetes who need it. Find out more at: https://worlddiabetesday.org/about/insulin-at-100/ Support: Published in collaboration with the International Diabetes Federation.
Juliana Chan, EASD 2020 – COVID-19 and type 1 diabetes
We spoke with Prof. Juliana Chan (The Chinese University of Hong Kong, Hong Kong) following her session on COVID-19 and the impact on patients with type 1 diabetes. Questions What key areas of diabetes and COVID-19 were discussed at EASD 2020? (0:05) How do you think the COVID-19 pandemic has affected treatment both now and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!